Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.55 |
| ▸ | CTSL | P07711 | 5/20 | 0.55 |
| ▸ | CTSS | P25774 | 5/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491395 | 1.00 | CTSK (0.55) | CTSKCTSLCTSSCACNA1BSYK | |
| SCHEMBL22975065 | 0.85 | SYK (0.60) | CTSKCTSLCTSSCACNA1BSYK | |
| SCHEMBL22975064 | 0.85 | SYK (0.60) | CTSKCTSLCTSSCACNA1BSYK | |
| SCHEMBL29401640 | 0.84 | CTSK (0.63) | CTSKCTSLCTSSSYKCTSB | |
| SCHEMBL344381 | 0.84 | CTSK (0.63) | CTSKCTSLCTSSSYKCTSB | |
| SCHEMBL344382 | 0.84 | CTSK (0.63) | CTSKCTSLCTSSSYKCTSB | |
| SCHEMBL7360681 | 0.83 | KLK7 (0.65) | CTSLCTSSCACNA1BSYKKLK7 | |
| SCHEMBL607263 | 0.82 | CTSK (0.61) | CTSKCTSLCTSSSYKCTSB | |
| SCHEMBL1410812 | 0.82 | CTSK (0.61) | CTSKCTSLCTSSSYKCTSB | |
| SCHEMBL1409909 | 0.82 | CTSK (0.61) | CTSKCTSLCTSSSYKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-1879895-B1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-06-08 | — | — | EP | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | CTSK 906/4885CTSL 2032/4885CTSS 1102/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | CTSK 1751/4885CTSL 848/4885CTSS 608/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | CTSK 476/4885CTSL 2209/4885CTSS 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.